Org-25935

Org-25935

SCHEMBL7703430

COc1ccc2c(c1)CCC(CN(C)CC(=O)O)C2c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A9

The experimentally established mechanism targets of Org-25935. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A9 known ✓ P48067 1/20 1.00
PPARD Q03181 3/20 0.47
TAS2R14 Q9NYV8 1/20 0.44
MTNR1B P49286 3/20 0.43
MTNR1A P48039 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
CA12 O43570 1/20 0.41
CA7 P43166 1/20 0.41
GRIN2B Q13224 4/20 0.40
GRIN1 Q05586 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Org-25935 SCHEMBL1761267 1.00 SLC6A9 (1.00) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
Org-25935 SCHEMBL27034881 1.00 SLC6A9 (1.00) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
Org-25935 SCHEMBL7703262 0.99 SLC6A9 (0.98) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
SCHEMBL19501070 0.94 SLC6A9 (0.88) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
Org-25935 SCHEMBL7703028 0.92 SLC6A9 (0.85) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
Org-25935 SCHEMBL7704305 0.92 SLC6A9 (0.85) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
SCHEMBL7708980 0.90 SLC6A9 (0.82) SLC6A9PPARDMTNR1BMTNR1A
SCHEMBL7698352 0.90 SLC6A9 (0.82) SLC6A9PPARDMTNR1BMTNR1A
SCHEMBL7700569 0.90 SLC6A9 (0.81) SLC6A9PPARDTAS2R14MTNR1BMTNR1A
SCHEMBL1761264 0.89 SLC6A9 (0.81) SLC6A9PPARDMTNR1BMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6410592-B1 THERAPY FOR CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS AKZO NOBEL N.V. (NL) 2002-06-25 US claimed
US-20240052418-A1 METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-02-15 US disclosed
US-11814681-B2 Method for predicting a subjects response to SLC modulator therapy THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-14 US disclosed
WO-2022192730-A1 COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA DISC MEDICINE, INC. (US) 2022-09-15 WO disclosed
US-20210254158-A1 METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. 2021-08-19 US disclosed
WO-2019046303-A1 A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2019-03-07 WO disclosed
US-20150141462-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-21 US disclosed